Excerpts from today's Inside Health Policy Daily News:

FDA is currently considering the appropriate naming convention for biosimilar and interchangeable products, and the agency will take into consideration comments submitted to dockets on proposed biosimilar products in finalizing biosimilar guidances and developing future policies, an agency spokesperson told Inside Health Policy...

“The FDA has opened several dockets for public comments on issues related to proposed biosimilar products and interchangeable products,” said the spokesperson. “Included in those comments are issues related to naming. We are carefully reviewing and considering the comments submitted to these public dockets. The FDA will take into account all comments received, as well as other relevant considerations, in finalizing the existing biosimilar guidance documents and developing future policies regarding biosimilar products and interchangeable products, including policies regarding naming.”...

To see complete article at Inside Health Policy (subscription required), click here.

Comment